ImmunoGen Scores $1.5M From Biogen Idec
Rebecca Zacks2/4/08
Cambridge, MA-based ImmunoGen (NASDAQ: IMGN) has snagged a $1.5 million milestone payment from Biogen Idec (NASDAQ: BIIB), the latest in a string of positive signs for a company that has struggled for decades, as David described last week. The payment was triggered by Biogen filing for FDA permission to being clinical trials of an anti-tumor agent that combines the two companies’ technologies.
